相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review
Xia Wang et al.
STROKE AND VASCULAR NEUROLOGY (2018)
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Bart M. Demaerschalk et al.
STROKE (2016)
Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke
C. S. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Statistical analysis plan for evaluating low-vs. standard-dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED)
Craig S. Anderson et al.
INTERNATIONAL JOURNAL OF STROKE (2015)
Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2x2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment
Yining Huang et al.
INTERNATIONAL JOURNAL OF STROKE (2015)
Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data The PRISMA-IPD Statement
Lesley A. Stewart et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Low-Dose Versus Standard-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke in Asian Populations A Meta-Analysis
Meng-Dong Liu et al.
MEDICINE (2015)
Low-Versus Standard-Dose Alteplase for Ischemic Strokes Within 4.5 Hours A Comparative Effectiveness and Safety Study
Beom Joon Kim et al.
STROKE (2015)
Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW)
Joung-Ho Rha et al.
INTERNATIONAL JOURNAL OF STROKE (2014)
Standard-Dose Intravenous Tissue-Type Plasminogen Activator for Stroke Is Better Than Low Doses
Xiaoling Liao et al.
STROKE (2014)
Guidelines for the Intravenous Application of Recombinant Tissue-type Plasminogen Activator (Alteplase), the Second Edition, October 2012: A Guideline From the Japan Stroke Society
Kazuo Minematsu et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2013)
Current status of intravenous thrombolysis for acute ischemic stroke in Asia
Vijay K. Sharma et al.
INTERNATIONAL JOURNAL OF STROKE (2011)
Effects of 0.6 mg/kg Intravenous Alteplase on Vascular and Clinical Outcomes in Middle Cerebral Artery Occlusion Japan Alteplase Clinical Trial II (J-ACT II)
Etsuro Mori et al.
STROKE (2010)
Thrombolysis With 0.6 mg/kg Intravenous Alteplase for Acute Ischemic Stroke in Routine Clinical Practice The Japan post-Marketing Alteplase Registration Study (J-MARS)
Jyoji Nakagawara et al.
STROKE (2010)
Routine Use of Intravenous Low-Dose Recombinant Tissue Plasminogen Activator in Japanese Patients General Outcomes and Prognostic Factors From the SAMURAI Register
Kazunori Toyoda et al.
STROKE (2009)
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
Werner Hacke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Combining propensity score matching and group-based trajectory analysis in an observational study
Amelia Haviland et al.
PSYCHOLOGICAL METHODS (2007)
Thrombolysis with alteplase for acute ischaemic stroke in the Safe implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study
Nils Wahlgren et al.
LANCET (2007)
Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset - Japan Alteplase Clinical Trial (J-ACT)
Takenori Yamaguchi et al.
STROKE (2006)
Marginal structural models and causal inference in epidemiology
JM Robins et al.
EPIDEMIOLOGY (2000)
分享论文
